9AM Hour: U.S.-Japan Yen Intervention, Stocks Rally As Oil Prices Slide, AstraZeneca-Bristol Myers M&A Buzz 8/3/26

Key takeaways

The U.S. and Japan conducted their first joint intervention to stabilize the yen, which is trading at multi-decade lows, reflecting geopolitical and economic tensions.
Major tech companies continue to show strong earnings and invest heavily in AI, but concerns about free cash flow and profitability remain, especially amid rising CapEx and market valuations.
Pharmaceutical consolidation, particularly the potential AstraZeneca-Bristol Myers merger, could reshape the sector and deliver significant synergies despite regulatory hurdles.
Market sentiment shows resilience but faces headwinds from geopolitical tensions, high bond issuance, and technological disruptions, especially related to AI advancements.
China's open-source AI models pose a significant challenge to global players and could influence the AI landscape’s strategic balance, with security implications.
Private equity firms are expanding their geographical footprint, with examples including Apollo moving into Texas, reflecting evolving investment strategies and regional considerations.

Summary

Market and Geopolitical News

This section covers recent notable events affecting markets, including the first U.S.-Japan joint intervention to support the yen, which has been trading at a 40-year low. It highlights concerns about Japan's economic struggles due to high energy costs and the U.S. government's supportive stance, including comments from the President about the yen and bond holdings. Discussions also touch upon bond market movements, interest rate expectations, and the influence of AI-driven bond issuance from hyperscalers, with projections reaching hundreds of billions of dollars. The impact of these macroeconomic factors on U.S. stock markets and investor sentiment is a central focus.

Corporate Earnings and Sector Performance

This part discusses recent earnings reports from major corporations like Amazon, Alphabet, Microsoft, and Meta, emphasizing their stock movements and future growth outlooks. The conversation highlights the robust performance of cloud services, AI investments, and the challenges some companies face with free cash flow and profitability. Attention is given to the technology sector’s valuation, the toll of high CapEx, and the outlook for future earnings, especially among big tech and AI companies.

Pharmaceutical and M&A Developments

Focus shifts to the pharma sector, specifically the potential merger talks between AstraZeneca and Bristol Myers Squibb, which could create a $400 billion pharmaceutical powerhouse. Discussions include regulatory considerations, potential benefits like R&D efficiencies, and recent stock performance of Bristol Myers. The episode examines the broader trend of pharma consolidation, regulatory hurdles, and the strategic moves by major companies in healthcare.

Investment Strategies and Market Sentiment

Analysis of recent market trends, including the performance of Starbucks, SpaceX, Alibaba, and other major stocks. The speakers evaluate the potential for recovery in stock losers, the impact of geopolitical tensions, and macroeconomic policies. They also discuss the significance of private equity and credit markets, the role of leverage, and the evolving investment landscape driven by AI developments and infrastructure investments.

Technology and AI Innovation

A detailed look into the advancements in AI models from Chinese open-source projects and global firms. The discussion emphasizes AI's growing influence in software engineering, autonomous coding, and rivalries between major entities like Anthropic and OpenAI. The presenters consider the potential impact of China's AI innovation and the implications for the global AI landscape, including security and regulatory concerns.

Show notes

On the first trading day of August, David Faber and Jim Cramer explored several developments of importance to the markets; The U.S.-Japan joint intervention to prop up a yen trading at 40-year lows; Stocks jump as oil prices tumble on hopes for a diplomatic solution to the U.S.-Iran conflict; AstraZeneca reportedly in merger talks with Bristol Myers Squibb to create a nearly $400 billion pharmaceutical giant. Also in focus: Starbucks gets upgraded, SpaceX hits new lows ahead of its Tuesday earnings report, Alibaba's AI bounce, a look at whether July's biggest stock losers can rebound in August, the Dow aims for a five-month win streak, the 19th anniversary of Cramer's "They know nothing!!" Fed rant.

Squawk on the Street Disclaimer

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.